GlaxoSmithKline (NYSE: GSK) Ebola vaccine produced responses from the immune system and didn’t raise safety concerns in a study with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE